Dynavax Technologies Corp. (NASDAQ:DVAX) soared by 38.19% on Wednesday to close at $15.38 per share after news of its acquisition by Sanofi for $2.2 billion. The offer price of $15.50 per share represents a premium of approximately 39% over its closing price on December 23. The acquisition includes Dynavax’s adult hepatitis B vaccine Heplisav-B and shingles vaccine candidate. CEO Ryan Spencer believes the merger will maximize the impact of their vaccine portfolio.

Read more at Yahoo Finance: Dynavax (DVAX) Rockets 38% on Sanofi $2-Billion Merger